[Stevens-Johnson syndrome induced by regorafenib in a patient with progressive recurrent rectal carcinoma].
A 55-year-old man with rectal carcinoma underwent lower anterior resection. Eight years after surgery, multiple metastases were detected in the liver, lung, and abdominal lymph nodes. The metastatic cancers were resistant to standard chemotherapy. Thus, regorafenib was administered to the patient. The patient presented symptoms of Stevens-Johnson syndrome (SJS) nine days after regorafenib administration, and hence, treatment was terminated. To treat SJS, he received oral and topical steroid therapies. SJS is an important adverse event that hinders the continuation of regorafenib treatment. Thus, it is necessary to continually check the patient's skin condition carefully, especially at early stages of treatment. To our knowledge, this is the first report of SJS arising during the course of regorafenib treatment.
Dept. of Surgery, Kurume University Kurume University Medical Cente.
Yutaro
Y
Mihara
Keizo
K
Yamaguchi
Takekuni
T
Nakama
Goichi
G
Nakayama
Hideki
H
Kamei
Nobuya
N
Ishibashi
Shinji
S
Uchida
Yoshito
Y
Akagi
Yutaka
Y
Ogata
D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D012008:Recurrence; D013262:Stevens-Johnson Syndrome / Q000209:etiology*
D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib